Keynote and Featured Speakers:
Comparing TCEs, ADCs, and CAR T Cell Therapy: What Have We Learned So Far?
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Novel Approaches for Extracellular Targeted Protein Degradation (eTPD)
James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
Moving beyond Pan-Cytotoxic Payloads for ADCs: Next-Generation ADCs with Novel Targeted Payloads
Gail D. Lewis, Distinguished Scientist, Discovery Oncology, Genentech, Inc.
The Story of Daiichi Sankyo's Pioneering DXd ADC Pipeline
Gerold Meinhardt, MD, PhD, Vice President & Head, Global Teams Lead, Early Oncology, Daiichi Sankyo, Inc.